EUROPEAN
COMMISSION

Brussels, XXX
SANTE/12067/2017 ANNEX CIS
(POOL/E4/2017/12067/12067-EN
ANNEX CIS.doc)
[…](2018) XXX draft

ANNEX

ANNEX

to the

COMMISSION IMPLEMENTING REGULATION (EU) .../...

approving penflufen as an active substance for use in biocidal products of product-type 8

ANNEX

Common Name	IUPAC Name Identification Numbers	Minimum degree of purity of the active substance[1]	Date of approval	Expiry date of approval	Product type	Specific conditions
Penflufen	IUPAC Name: 5-fluoro-1,3-dimethyl-N-{2-[(2RS)-4-methylpentan-2-yl]phenyl}-1H-pyrazole-4-carboxamide EC No: not available CAS No: 494793-67-8	980g/kg (1:1 ratio (R:S) ratio of enantiomers)	1 January 2019	31 December 2028	8	The authorisations of biocidal products are subject to the following conditions: 1) The product assessment shall pay particular attention to the exposures, the risks and the efficacy linked to any uses covered by an application for authorisation, but not addressed in the Union-level risk assessment of the active substance. 2) In view of the risks identified for the uses assessed, the product assessment shall pay particular attention to: a) industrial and professional users; b) soil and groundwater for wood in service that will be exposed to frequent weathering. 3) In view of the risks identified for soil, labels, and, where provided, safety data sheets of product authorised shall indicate that industrial application shall be conducted within a contained area or on impermeable hard standing with bunding, that freshly treated timber shall be stored after treatment under shelter or on impermeable hardstanding, or both, to prevent direct losses to soil or water, and that any losses from the application of the product shall be collected for reuse or disposal. The placing on the market of treated articles is subject to the following condition: The person responsible for the placing on the market of a treated article treated with or incorporating penflufen shall ensure that the label of that treated article provides the information listed in the second subparagraph of Article 58(3)

[1] The purity indicated in this column was the minimum degree of purity of the active substance evaluated. The active substance in the product placed on the market can be of equal or different purity if it has been proven to be technically equivalent to the evaluated active substance.

						of Regulation (EU) No 528/2012.